Autolus Therapeutics (AUTL) Research & Development (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Research & Development data on file, last reported at $35.6 million in Q4 2025.

• Quarterly Research & Development rose 15.58% year-over-year to $35.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $117.7 million (down 14.99% YoY) and the FY2025 annual result came in at $117.7 million, down 14.99% from the prior year.
• Research & Development climbed to $35.6 million in Q4 2025, from $27.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $40.3 million in Q3 2024 to a low of $7.5 million in Q4 2022.
• A 5-year average of $29.8 million and a median of $30.8 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2021 — Research & Development plunged 59.5% — and 2023, when it jumped 397.39%.
• Tracing AUTL's Research & Development over 5 years: stood at $15.7 million in 2021, then tumbled by 51.88% to $7.5 million in 2022, then jumped by 397.39% to $37.5 million in 2023, then fell by 17.88% to $30.8 million in 2024, then grew by 15.58% to $35.6 million in 2025.
• The last three Research & Development figures came in at $35.6 million (Q4 2025), $27.9 million (Q3 2025), and $27.4 million (Q2 2025), per Business Quant data.